5:40 PM
 | 
Feb 14, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor.

The primary endpoint measured the percent of patients who achieved a histologic improvement in fibrosis of at least one stage according to the NASH Clinical Research Network (CRN) classification without worsening...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >